UNSPSC 51286703: Iclaprim

This classification denotes an antibiotic with the molecular formula C19H22N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 42445HUU0O, chemically known as 5-((2rs)-2-cyclopropyl-7,8-dimethoxy-2h-chromen-5-ylmethyl)pyrimidine-2,4-diamine but more generally known as iclaprim, which bears US NIH Compound Identifier 213043. European Medicines Agency schedules Iclaprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32201.

The term ICLAPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 17, No. 4, 2003, List 50). The World Health Organization schedules iclaprim in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C(C2CC2)C=CC2C1C(OC)C(OC)CC2CC1C(NC(NC1)N)N.

UNSPSC 51286703 Iclaprim is a Commodity code under which state and local governments procure specific pharmaceutical products, though recent activity shows limited relevance to the code's nominal scope. The two most recent opportunities on file involve unrelated products: antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) supplied through a piggyback consortium contract, and naloxone with drug deactivation systems procured for community health initiatives. Neither aligns with iclaprim, an antimalarial pharmaceutical, suggesting the code may be misapplied to these solicitations or the source data contains tagging errors. The issuing bodies represent different jurisdictional tiers — a state health department (Illinois Department of Public Health) and a county health agency (Seminole County, Florida) — but the pharmaceutical procurement activity itself does not reflect the code's intended commodity.

The geographic footprint captured by recent tagging includes Illinois and Florida, though the limited number of relevant opportunities and the apparent mismatch between code and actual scope limit confidence in whether this code genuinely supports sustained state and local demand. The Illinois Department of Public Health awarded a $2,999,999.11 contract to Chartwell Rx LLC through the MMCAP Infuse consortium in August 2026 covering antibiotic tablets, while Seminole County issued an IFB in June 2026 for naloxone and drug deactivation systems with quarterly delivery requirements. Neither procurement reflects iclaprim demand, and no open solicitations under the code are currently available. Business development professionals should verify whether iclaprim opportunities exist in other jurisdictions or whether procurement officers are consistently misapplying this code to unrelated pharmaceutical categories.